Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Macdonald

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
BMJ Open|February 2, 2026
Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare dataWilliam H Nailon, David J Noble, Ewen Harrison, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
BMJ Open|February 2, 2026
Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare dataWilliam H Nailon, David J Noble, Ewen Harrison, et al.
Pageof 3